Thais Megid

What makes a good oncologist? 203 Art of Oncology essays. 242 authors. 7 themes. Practicing patient-centered care, cultivating meaningful relationships, communicating skillfully and authentically, exercising emotional intelligence, managing the burden of cancer care, welcoming varied mindsets, and pursuing learning and leadership. Notable disconnect: ACGME wants trainees to independently manage their well-being. Oncologists writing in JCO say good oncologists seek support, create space for grief, and practice self-care communally. Different philosophy of sustainability entirely. And patients and caregivers weren’t the authors here. Any framework for good doctoring in oncology that doesn’t center their voices is incomplete.

Organ preservation in esophageal cancer (e.g., SANO) is promising—but can we trust pCR in adenocarcinoma pts? Our meta-analysis (>7000 pts) found pCR is a weak surrogate for OS in GEA. *immunotherapy trials may be different DOI: 10.1016/j.ejca.2026.116602

Is pCR a surrogate EP for OS is gastric/esophageal adenocarcinoma?📈 Maybe not ! 👀 Different results between GEJ and gastric cancer 💥 SCC was not included in this MA but it will be presented soon! 🔥

Ever heard of negative hyperselection in EGFR therapy? 🚨 EGFRi help in RAS/BRAF WT mCRC, but resistance is common. 🔬 Resistance is driven by HER2/MET amp, PI3K/AKT act, EGFR mut & more. 🧬 Neg hyperselection = refine patient selection for EGFRi 🔗 10.3390/cancers17172804

This will support even more our HPB tumor boards discussions !

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25% 🧬 TP53 (Li-Fraumeni): RR 7–10 | Risk 5–15% 🧬 BRCA2 / PALB2 / ATM: RR 2–6 | Risk ~5–10% 🧬 FPC (Familial Pancreatic Ca): RR 4–32 (family burden dependent) 📊 Even rare syndromes (like STK11, CDKN2A, TP53) carry >10× risk vs general population! 💡 Emerging targeted trials: • TNG260 + pembro for STK11 (NCT05887492) • TCR-T cell therapy in dev for TP53 👉 Pancreas screening may be justified in select germline carriers (RR >5 + FHx) #PancreaticCancer #Genomics #GIcancer #PrecisionOncology @myESMO @MyriamChalabi @CathyEngMD @OncoAlert @OncBrothers

@ArndtVogel @medoncdoc @myESMO @EASLedu @ILCAnews Great news !

🔥Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer🔥 👉great news, another 🇪🇺 approval in BTC 🧐Don't forget IHC Her2 testing in BTC! @myESMO @EASLedu @ILCAnews @curecc

This is an alert for physicians and patients!

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO

Presented at #ASCO25: In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade. Full DESTINY-Gastric04 trial: nej.md/4k1dwjN @ASCO

#MATTERHORN trial was one of the best studies at #ASCO2025 - addition of durvalumab to SOC preoperatively FLOT was positive for EFS in gastric cancer pts. That study brings #hope and possible increased chances of #cure. Looking forward to seeing the survival data in the future

Excited to share that I’ve graduated from the VA Quality Scholars Advanced Fellowship! Grateful to the 2 years VAQS program and University of Toronto for this incredible opportunity. Looking forward to advancing Quality Improvement and Patient Safety in cancer care! #VAQS #UofT

📄 Our publication in JCO Global Oncology: ascopubs.org/doi/10.1200/GO… We analyzed global trends in early-onset pancreatic cancer: 🔍 Key insights (1990–2021): ✅ Incidence ↑ 63% ✅ Mortality ↑ 57%, especially in middle SDI regions ⚠️ Leading risk factors: Smoking and Obesity

💊 Can DFS be used as a surrogate for OS in early-stage pancreatic cancer trials? 📈 In a meta-analysis of 29 RCTs (n=6777), DFS strongly correlated with OS (R=0.70 adjuvant | R=0.90 neoadjuvant). 📍 DFS may be a reliable surrogate endpoint for OS. bmjoncology.bmj.com/content/bmjonc…

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC & endometrial. #MSI #Immunotherapy #Biomarkers 🔗 nature.com/articles/s4157…

@CamilaBragancaX @MDAndersonNews @JIPOEditors @mirella_nardo @BettzyStephen @jtmoyers @VivekSubbiah @DavidHongMD @ANaingMD Congrats! Amazing work

Although efficacy is modest, the results of this cohort help us understand treatment dynamics and possible biomarkers for response to immunotherapy in rare tumors. Happy to have contributed to this publication! @MDAndersonNews @JIPOEditors ➡️ pmc.ncbi.nlm.nih.gov/articles/PMC11…

@BiachiTiago Amazing

Really excited to share that my investigator initiated trial using enfortumab vedotin in advanced #colorectalcancer and #hcc is now open. Nectin-4 is highly expressed in both tumors and more options are urgently needed. Many thanks to Moffitt staff, Astellas and Dr Richard Kim for all support! @MoffittNews @CCAlliance @FightCRC clinicaltrials.gov/study/NCT06553…

Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues @OncoAlert @AnnPartridgeMD @oncofertility Link: ascopubs.org/doi/10.1200/JC…

DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! @OncoAlert @oncodaily @DaiichiSankyoUS @AstraZeneca daiichisankyo.com/files/news/pre…

Interesting findings but concerning …